ILLUMINA TO CONDUCT LARGE-SCALE GENOTYPING STUDY FOR NORTH AMERICAN RHEUMATOID ARTHRITIS CONSORTIUM

SAN DIEGO, CALIFORNIA, September 16, 2004

Illumina, Inc. (NASDAQ: ILMN) announced today that it has signed a commercial agreement to conduct an extensive, two-phase genotyping study for the North American Rheumatoid Arthritis Consortium (NARAC) to identify genes associated with this complex and debilitating disease. The NARAC study will be led by Peter K. Gregersen, M.D., who directs the Robert S. Boas Center for Genomics & Human Genetics at the Institute for Medical Research (Manhasset, NY), part of the North Shore-Long Island Jewish Health System. Dr. Gregersen is also the Principal Investigator of the Multiple Autoimmune Disease Genetics Consortium, an NIH-funded effort to identify common genes that underlie autoimmune diseases.

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 2.1 million Americans -- roughly 1% of the population -- and is characterized by painful inflammation of the joints. RA is complex: there is a genetic component that confers disease susceptibility, coupled with additional components including environmental factors that activate RA-related genes implicated in the disease. The scale of the study is consistent with the complexity of the disease: over 25 million genotypes will be generated by Illumina and analyzed by Dr. Gregersen and colleagues.

"Illumina played an active and collaborative role in experimental design," stated Dr. Gregersen. "We were particularly pleased with the recommendation to break the study into two, back-to-back components. This will enable us to perform extensive data analysis using Illumina's Linkage IV mapping panel and then quickly develop a custom SNP panel for more detailed follow-on studies."

Phase One of the RA study will involve genetic mapping of over 3125 samples using Illumina's standard Linkage IV single nucleotide polymorphism (SNP) Panel, which includes over 5800 SNP markers distributed evenly across the genome. Phase Two will involve development of a custom panel of SNP loci for dense mapping of specific candidate gene regions identified in Phase One.

"Enabling the life science community to expand understanding of the genetic cause of disease is a core application of our BeadArray(TM) technology platform," commented Jay Flatley, Illumina President and CEO. "We're very pleased to work with Peter Gregersen and his NARAC collaborators and we look forward to contributing meaningfully to a growing body of knowledge about rheumatoid arthritis and related diseases."

Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genome centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and
pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, market acceptance of Illumina's BeadArray-based products, Illumina's ability to fully develop and commercialize its BeadArray technologies, the Company's ability to successfully commercialize its integrated BeadLab and BeadStation systems for high-throughput genetic analysis, to continue to attract and retain customers in its services and oligonucleotide synthesis operations, to fully develop its BeadArray technologies, to develop and deploy new gene expression profiling and proteomics applications for its platform technology, to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

##

Contacts:

Jay Flatley  
President & CEO  
1.858.202.4501  
jflatley@illumina.com

or

William Craumer  
Director, Corporate Communications  
1.858.202.4667  
mer@illumina.com